Loading…
TOR inhibitors: from mammalian outcomes to pharmacogenetics in plants and algae
Pharmacology of TOR inhibitors has improved knowledge of the mammalian TOR pathway. This review updates why and how pharmacogenetics is proving effective in deciphering the TOR pathway in photosynthetic organisms. Abstract Target of rapamycin (TOR) is a conserved eukaryotic phosphatidylinositol 3-ki...
Saved in:
Published in: | Journal of experimental botany 2019-04, Vol.70 (8), p.2297-2312 |
---|---|
Main Authors: | , |
Format: | Article |
Language: | English |
Subjects: | |
Citations: | Items that this one cites Items that cite this one |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Summary: | Pharmacology of TOR inhibitors has improved knowledge of the mammalian TOR pathway. This review updates why and how pharmacogenetics is proving effective in deciphering the TOR pathway in photosynthetic organisms.
Abstract
Target of rapamycin (TOR) is a conserved eukaryotic phosphatidylinositol 3-kinase-related kinase that regulates growth and metabolism in response to environment in plants and algae. The study of the plant and algal TOR pathway has largely depended on TOR inhibitors first developed for non-photosynthetic eukaryotes. In animals and yeast, fundamental work on the TOR pathway has benefited from the allosteric TOR inhibitor rapamycin and more recently from ATP-competitive TOR inhibitors (asTORis) that circumvent the limitations of rapamycin. The asTORis, developed for medical application, inhibit TOR complex 1 (TORC1) more efficiently than rapamycin and also inhibit rapamycin-resistant TORCs. This review presents knowledge on TOR inhibitors from the mammalian field and underlines important considerations for plant and algal biologists. It discusses the use of rapamycin and asTORis in plants and algae and concludes with guidelines for physiological studies and genetic screens with TOR inhibitors. |
---|---|
ISSN: | 0022-0957 1460-2431 |
DOI: | 10.1093/jxb/erz053 |